secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-04-07T23:59:59+00:00
Accession:  0001558370-25-004507
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Phase 3 TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in 120 patients
--------------------------------------------------------------------------------

- Mean BMI change of -16.5% on setmelanotide vs +3.3% for placebo at 52 weeks (p<0.0001); 80% achieved ≥5% BMI reduction.
- Regulatory submissions in US and EU planned for Q3 2025; setmelanotide could become first approved therapy for acquired hypothalamic obesity.
- Cash and short-term investments expected to fund operations into 2027.
- No new safety signals; most common AEs were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, headache.
- Secondary endpoints: 83% of patients achieved ≥5% BMI or ≥0.2 BMI Z-score reduction; hunger score improved (p=0.003).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/0001558370-25-004507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025004507/rytm-20250407x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer